ClinicalTrials.gg

Program

Febuxostat

Also written as “Febuxostat XR”, “Febuxostat 40 mg” and “Febuxostat 80 mg”.

Its studies are mostly in Gout · Hyperuricemia · Tumor Lysis Syndrome · Polycystic Kidney, Autosomal Dominant · Cardiovascular Diseases, led by 7 companies.

Furthest: phase 4, since Jan 7, 201328 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda180 open or runningphase 4since Jan 7, 2013Jan 29, 2005none ahead
Menarini Group30 open or runningphase 4since Jul 7, 2015Nov 7, 2012none ahead
AstraZeneca20 open or runningphase 2since Sep 19, 2014Jun 18, 2013none ahead
SK Chemicals20 open or runningphase 3since Jan 12, 2009Jan 12, 2009none ahead
Astellas Pharma10 open or runningphase 3since Nov 27, 2012Nov 27, 2012none ahead
Getz Pharma10 open or runningphase 4since Nov 2, 2015Nov 2, 2015none ahead
Pharmtechnology10 open or runningphase 1since Apr 15, 2019Apr 15, 2019none ahead

Also a collaborator on its studies: altasciences-company-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Jan 29, 2005.

  1. Nov 7, 2012Menarini Group's first study: phase 3 study in Tumor Lysis SyndromeNew to Menarini GroupMenarini Group · NCT01724528 · 346 enrolled
  2. Nov 27, 2012Astellas Pharma's first study: phase 3 study in GoutNew to Astellas PharmaAstellas Pharma · NCT01736514 · 109 enrolled · Taiwan
  3. Jan 7, 2013Phase 4 study in Coronary Artery DiseaseTakeda · NCT01763996 · 30 enrolled · United States
  4. Jun 18, 2013AstraZeneca's first study: phase 1 study in HealthyNew to AstraZenecaAstraZeneca · NCT01883167 · 21 enrolled · United States
  5. Apr 29, 2014Phase 2 study in GoutTakeda · NCT02128490 · 189 enrolled · United States
  6. May 13, 2014Phase 3 study in GoutTakeda · NCT02139046 · 1,790 enrolled · United States
  7. Sep 19, 2014Phase 2 study in GoutAstraZeneca · NCT02246673 · 64 enrolled · United States
  8. Feb 22, 2015Phase 1 study in GoutTakeda · NCT02374164 · 36 enrolled · United States
  9. Mar 3, 2015Phase 1 study in Healthy VolunteersTakeda · NCT02382640 · 36 enrolled · United States
  10. Jul 7, 2015Phase 4 study in GoutMenarini Group · NCT02500641 · 196 enrolled · Germany, Italy, Netherlands and more
  11. Jul 20, 2015Phase 1 study in Healthy VolunteersTakeda · NCT02504320 · 78 enrolled · United States
  12. Nov 2, 2015Getz Pharma's first study: phase 4 study in HyperuricemiaNew to Getz PharmaGetz Pharma · NCT02600780 · 50 enrolled · Pakistan
  13. May 29, 2018Phase 2 study in Tumor Lysis SyndromeMenarini Group · NCT03605212 · 30 enrolled · Bulgaria, Hungary, Italy and more
  14. Apr 15, 2019Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT03918551 · 50 enrolled · Canada

TargetBeta

XDH →read by rule
“Xanthine dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT03918551Bioequivalence · Canada1CompletedPharmtechnologyJun 6, 201950
NCT03605212Tumor Lysis Syndrome · Bulgaria, Hungary, Italy and more2TerminatedMenarini GroupJul 25, 201830
NCT02600780Hyperuricemia · Pakistan4CompletedGetz PharmaDec 201450
NCT02504320Healthy Volunteers · United States1CompletedTakedaSep 201578
NCT02500641Gout · Germany, Italy, Netherlands and more4CompletedMenarini GroupMay 10, 2017196
NCT02382640Healthy Volunteers · United States1CompletedTakedaMay 201536
NCT02374164Gout · United States1CompletedTakedaMar 201536
NCT02246673Gout · United States2CompletedAstraZenecaJul 201564
NCT02139046Gout · United States3CompletedTakedaNov 20151,790
NCT02128490Gout · United States2CompletedTakedaSep 2015189
NCT01883167Healthy · United States1CompletedAstraZenecaSep 201321
NCT01763996Coronary Artery Disease · United States4CompletedTakedaMar 201530
NCT01736514Gout · Taiwan3CompletedAstellas PharmaFeb 2012109
NCT01724528Tumor Lysis Syndrome3CompletedMenarini GroupOct 2013346
NCT01563432Gout · Korea, Republic of1CompletedSK ChemicalsFeb 201230
NCT01549977Angina Pectoris · United States2TerminatedTakedaNov 20121
NCT01496469Hypertension · United States2CompletedTakedaAug 2014121
NCT01101035Cardiovascular Diseases · United States, Mexico3CompletedTakedaMay 15, 20176,198
NCT01082640Renal Insufficiency · United States2CompletedTakedaMay 201296
NCT01078389Gout · United States2CompletedTakedaSep 2013314
NCT01077284Kidney Calculi · United States2CompletedTakedaNov 201199
NCT00821392Gout3CompletedSK ChemicalsSep 2007181
NCT00430248Gout · United States3CompletedTakedaMar 20082,269
NCT00175019Gout3CompletedTakedaFeb 20071,086
NCT00174941Gout2CompletedTakedaDec 2006116
NCT00174967Gout2CompletedTakedaJul 2001153
NCT00174915Gout3CompletedTakedaApr 20041,072
NCT00102440Gout3CompletedTakedaFeb 2004760

How it is read

Names in the registry

  • “Febuxostat”, 32 entries
  • “Febuxostat XR”, 4 entries
  • “Febuxostat 40 mg”, 3 entries
  • “Febuxostat 80 mg”, 2 entries
  • “SHR4640 ; Febuxostat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.